{
  "id": "56bc9268ac7ad1001900001b",
  "type": "factoid",
  "question": "What molecule is targeted by brodalumab?",
  "ideal_answer": "Interleukin-17. Brodalumab is anti interleukin-17 monoclonal antibody.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/25093016",
    "http://www.ncbi.nlm.nih.gov/pubmed/26422722",
    "http://www.ncbi.nlm.nih.gov/pubmed/24646743",
    "http://www.ncbi.nlm.nih.gov/pubmed/24200404",
    "http://www.ncbi.nlm.nih.gov/pubmed/24552447",
    "http://www.ncbi.nlm.nih.gov/pubmed/24918373",
    "http://www.ncbi.nlm.nih.gov/pubmed/25599143",
    "http://www.ncbi.nlm.nih.gov/pubmed/25713988",
    "http://www.ncbi.nlm.nih.gov/pubmed/25246805",
    "http://www.ncbi.nlm.nih.gov/pubmed/22455412"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: Early clinical studies suggested that the anti-interleukin-17 receptor A monoclonal antibody brodalumab has efficacy in the treatment of psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26422722",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "METHODS: We reviewed the results of the phase II clinical trials for the anti-IL-17 agents secukinumab, ixekizumab and brodalumab in order to assess the efficacy and safety profile of each agent.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24552447",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These include the IL-17 antagonists, secukinumab, brodalumab and ixekizumab; the IL-23 antagonists, guselkumab and tildrakizumab; and the oral small molecule therapies, tofacitinib and apremilast. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25713988",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RECENT FINDINGS: New drugs that are designed to inhibit steps in this pathway, the IL12/IL23 inhibitor, ustekinumab, the IL17A inhibitors secukinumab and ixekizumab, the IL17A receptor inhibitor, brodalumab, and the IL23 inhibitors guselkumab and tildrakizumab, have demonstrated significant effectiveness in treating these diseases, particularly psoriasis, psoriatic arthritis and ankylosing spondylitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25599143",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24918373",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22455412",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24200404",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24646743",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "The three new therapies with biologic drugs - brodalumab, secukinumab, and ixekizumab - all target the IL-17 signaling pathway. Secukinumab and ixekizumab neutralize IL-17A, while brodalumab blocks its receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25246805",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Brodalumab is a human monoclonal antibody that targets IL-17 receptor A,",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25093016",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Interleukin-17"
}